CTIS2023-504514-29-00进行中（未招募）1 期
2138-CL-0101
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 240
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
This is a first in human study, in patients with severe bleeding disorder (hemophilia A), who has developed inhibitory antibodies against coagulation factor VIII.The aim is to study the safety and efficacy of dendritic cells, originating from the patient itself. The dendritic cells has been loaded with coagulation factor VIII for an improved immunological tolerance. (TOLER8)CTIS2022-502030-12-01Idogen AB6
招募中
1 期
Phase 1b study investigating the association of NP137 with mFOLFIRINOX in locally advanced pancreatic ductal adenocarcinoma LAP NET 1pancreatic ductal adenocarcinomaCTIS2022-500905-42-00niversity Hospital Grenoble52
招募中
1 期
First-in human, dose escalation and cohort expansion study for the evaluation of LB-208 (HTR1B antagonist) in adult patients with relapsed or refractory solid tumours and lymphomaymphoma, Solid tumorMedDRA version: 20.0Level: HLGTClassification code: 10025323Term: Lymphomas NEC Class: 10029104MedDRA version: 21.1Level: LLTClassification code: 10065147Term: Malignant solid tumor Class: 10029104CTIS2023-509532-25-00eukos Biotech S.L.42
招募中
1 期
A PHASE I STUDY OF THE CEACAM5 x CD3 ANTIBODY NILK-2301 IN COLORECTAL CANCERCTIS2023-508058-24-01ovImmune S.A.12
进行中（未招募）
1 期
A PHASE I STUDY OF THE CEACAM5 x CD3 ANTIBODY NILK-2301 IN COLORECTAL CANCEROCALLY ADVANCED OR METASTATIC LOW TUMOR VOLUME COLORECTAL CANCERCTIS2023-508058-24-00ovImmune S.A.12